03/29/2016 14:00 US/Eastern
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
- See more at: https://co28170.omnovia.com/register/22391458652488#sthash.IGh2VMev.dpuf
03/29/2016 14:00 US/Eastern
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
- See more at: https://co28170.omnovia.com/register/22391458652488#sthash.IGh2VMev.dpuf
03/29/2016 14:00 US/Eastern
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
- See more at: https://co28170.omnovia.com/register/22391458652488#sthash.IGh2VMev.dpuf
03/29/2016 14:00 US/Eastern
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
- See more at: https://co28170.omnovia.com/register/22391458652488#sthash.IGh2VMev.dpuf
03/29/2016 2:00pm US/Eastern
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
- See more at: https://co28170.omnovia.com/register/22391458652488#sthash.IGh2VMev.dpuf
The greatest asset of a young biotech company is its intellectual property. Strategic decisions made during the initial organization and early growth of your company have a lasting impact on its success. In this webinar, we will address how inventorship and ownership of patent rights have given rise to disputes between biotech companies. We will review how the changing patent landscape has affected the industry, discuss the types of biotechnology that can be patented, and explore the economic implications of the first wave of biosimilars coming on to the market in the U.S. today
Click here to Register
Lessons from the Trenches: Locking Down Your Patent Rights
Matt McFarlane, Ph.D., Principal
Sharon Roberg-Perez, Ph.D., Principal
Robins Kaplan LLP
Developments in the Law Concerning Patentable Subject Matter: Is Your Invention Eligible for Protection?
Lee Crews, Ph.D., Partner
O&R Patent Law
Biosimilars vs. Biologics: What Can We Expect?
Lisa Cameron, Ph.D., Partner
The Brattle Group
Click here to Register
